CN/EN

Search
Hotline:86-512-62697697

research&development

Hotline:
86-512-62697697
Add.:
Room 303 & 305, Building 15, Suzhou Medpark, No. 8 Jingfeng Road, Suzhou New District
首页研究开发 : Research and Development OverviewResearch and Development Overview
The company has developed a series of monoclonal antibodies that antagonize costimulatory molecules, a target molecule which is the most economically promising among antibodies applied in medical treatment. In the field of oncotherapy, PD-1, B7-H1, B7H3, B7H4, Tim-3 and CD40 has become a research hotspot of international developmental prospect, and they offer a unique target for antibody industry to develop independent intellectual property rights.